Real-world experience of OnabotulinumtoxinA treatment in female patients with chronic migraine: a qualitative study using in-depth interviews

References

• Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1–14. doi: 10.1177/0333102417738202.
   PubMed Web of Science ®Google Scholar
• Kung D, Rodriguez G, Evans R. Chronic migraine: diagnosis and management. Neurol Clin. 2023;41(1):141–159. doi: 10.1016/j.ncl.2022.05.005.
   PubMed Web of Science ®Google Scholar
• Buse DC, Greisman JD, Baigi K, et al. Migraine progression: a systematic review. Headache. 2019;59(3):306–338. doi: 10.1111/head.13459.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Lipton RB. Concepts and mechanisms of migraine chronification. Headache. 2008;48(1):7–15. doi: 10.1111/j.1526-4610.2007.00969.x.
   PubMed Web of Science ®Google Scholar
• Xu J, Kong F, Buse DC. Predictors of episodic migraine transformation to chronic migraine: a systematic review and meta-analysis of observational cohort studies. Cephalalgia. 2020;40(5):503–516. doi: 10.1177/0333102419883355.
   PubMed Web of Science ®Google Scholar
• Natoli JL, Manack A, Dean B, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30(5):599–609. doi: 10.1111/j.1468-2982.2009.01941.x.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Manack Adams A, Buse DC, et al. A comparison of the chronic migraine epidemiology and outcomes (CaMEO) study and American migraine prevalence and prevention (AMPP) study: demographics and headache-related disability. Headache. 2016;56(8):1280–1289. doi: 10.1111/head.12878.
   PubMed Web of Science ®Google Scholar
• Meletiche DM, Lofland JH, Young WB. Quality-of-life differences between patients with episodic and transformed migraine. Headache. 2001;41(6):573–578. doi: 10.1046/j.1526-4610.2001.041006573.x.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Rapoport AM, Lipton RB, et al. Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic migraine. Headache. 2003;43(4):336–342. doi: 10.1046/j.1526-4610.2003.03068.x.
   PubMed Web of Science ®Google Scholar
• Blumenfeld AM, Varon SF, Wilcox TK, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the international burden of migraine study (IBMS). Cephalalgia. 2011;31(3):301–315. doi: 10.1177/0333102410381145.
   PubMed Web of Science ®Google Scholar
• Paschoal JK, Lin J, Pinho RS, et al. Psychiatric symptoms may contribute to poor quality of life in adolescents with migraine. Pediatr Int. 2013;55(6):741–747. doi: 10.1111/ped.12178.
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Lipton RB, Dodick DW, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007;47(2):170–180. doi: 10.1111/j.1526-4610.2006.00684.x.
   PubMed Web of Science ®Google Scholar
• Diener HC, Bussone G, Van Oene JC, et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27(7):814–823. doi: 10.1111/j.1468-2982.2007.01326.x.
   PubMed Web of Science ®Google Scholar
• Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):793–803. doi: 10.1177/0333102410364676.
   PubMed Web of Science ®Google Scholar
• Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804–814. doi: 10.1177/0333102410364677.
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377(22):2113–2122. doi: 10.1056/NEJMoa1709038.
   PubMed Web of Science ®Google Scholar
• Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16(6):425–434. doi: 10.1016/S1474-4422(17)30083-2.
   PubMed Web of Science ®Google Scholar
• Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211–e2221. doi: 10.1212/WNL.0000000000006640.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Goadsby PJ, Smith J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology. 2020;94(13):e1365–e1377. doi: 10.1212/WNL.0000000000009169.
   PubMed Web of Science ®Google Scholar
• Lanteri-Minet M, Ducros A, Francois C, et al. Effectiveness of onabotulinumtoxinA (BOTOX®) for the preventive treatment of chronic migraine: a meta-analysis on 10 years of real-world data. Cephalalgia. 2022;42(14):1543–1564. doi: 10.1177/03331024221123058.
   PubMed Web of Science ®Google Scholar
• Blumenfeld AM, Stark RJ, Freeman MC, et al. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13. doi: 10.1186/s10194-018-0840-8.
   PubMedGoogle Scholar
• Rothrock JF, Adams AM, Lipton RB, et al. FORWARD study: evaluating the comparative effectiveness of OnabotulinumtoxinA and topiramate for headache prevention in adults with chronic migraine. Headache. 2019;59(10):1700–1713. doi: 10.1111/head.13653.
   PubMed Web of Science ®Google Scholar
• Altamura C, Brunelli N, Viticchi G, et al. Quantitative and qualitative pain evaluation in response to OnabotulinumtoxinA for chronic migraine: an observational real-life study. Toxins. 2023;15(4):284. doi: 10.3390/toxins15040284.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration (FDA). Developing and submitting proposed draft guidance related to patient experience data, guidance for industry and other stakeholders. 2018. https://www.fda.gov/media/119542/download.
   Google Scholar
• Okun S. The missing reality of real life in real-world evidence. Clin Pharmacol Ther. 2019;106(1):136–138. doi: 10.1002/cpt.1465.
   PubMed Web of Science ®Google Scholar
• Creswell JW, Poth CN. Qualitative inquiry and research design. Choosing among five approaches. 4th ed. Thousand Oaks (CA): SAGE; 2018.
   Google Scholar
• Korstjens I, Moser A. Series: Practical guidance to qualitative research. Part 2: context, research questions and designs. Eur J Gen Pract. 2017;23(1):274–279. doi: 10.1080/13814788.2017.1375090.
   PubMed Web of Science ®Google Scholar
• Jacinto J, Lysandropoulos A, Leclerc M, et al. Experiences of patients with poststroke spasticity throughout a botulinum toxin treatment cycle: results from a prospective ethnographic study. Front Neurol. 2022;13:946500. doi: 10.3389/fneur.2022.946500.
   PubMed Web of Science ®Google Scholar
• Kerstens HCJW, Satink T, Nijkrake MJ, et al. Experienced consequences of spasticity and effects of botulinum toxin injections: a qualitative study amongst patients with disabling spasticity after stroke. Disabil Rehabil. 2021;43(25):3688–3695. doi: 10.1080/09638288.2020.1746843.
   PubMed Web of Science ®Google Scholar
• Arai S, Fukase Y, Okii A, et al. Selection process for botulinum toxin injections in patients with chronic-stage hemiplegic stroke: a qualitative study. BMC Med Inform Decis Mak. 2019;19(1):280. doi: 10.1186/s12911-019-1003-9.
   PubMed Web of Science ®Google Scholar
• Nguyen L, Di Rezze B, Mesterman R, et al. Effects of botulinum toxin treatment in nonambulatory children and adolescents with cerebral palsy: understanding parents’ perspectives. J Child Neurol. 2018;33(11):724–733. doi: 10.1177/0883073818786567.
   PubMed Web of Science ®Google Scholar
• Karadag-Saygi E, Kenis-Coskun Ö, Unalan PC, et al. Pros and cons of botulinum toxin injection therapy in cerebral palsy: a qualitative study exploring caregivers’ perspective. Child Care Health Dev. 2022;48(1):150–158. doi: 10.1111/cch.12915.
   PubMed Web of Science ®Google Scholar
• Page AD, Elhayek N, Baylor C, et al. Exploring the psychosocial impact of botulinum toxin type a injections for individuals with oromandibular dystonia: a qualitative study of patients’ experiences. Am J Speech Lang Pathol. 2021;30(3S):1314–1328. doi: 10.1044/2020_AJSLP-20-00124.
   PubMedGoogle Scholar
• Baylor CR, Yorkston KM, Eadie TL, et al. The psychosocial consequences of BOTOX injections for spasmodic dysphonia: a qualitative study of patients’ experiences. J Voice. 2007;21(2):231–247. doi: 10.1016/j.jvoice.2006.01.007.
   PubMed Web of Science ®Google Scholar
• Wilderman I, Tallarigo D, Pugacheva-Zingerman O. A qualitative study to explore patient perspectives of prophylactic treatment with OnabotulinumtoxinA for chronic migraine. Pain Ther. 2021;10(2):1523–1536. doi: 10.1007/s40122-021-00316-2.
   PubMed Web of Science ®Google Scholar
• Jack SM, Phoenix M. Qualitative health research in the fields of developmental medicine and child neurology. Dev Med Child Neurol. 2022;64(7):830–839. doi: 10.1111/dmcn.15182.
   PubMed Web of Science ®Google Scholar
• Bradshaw C, Atkinson S, Doody O. Employing a qualitative description approach in health care research. Glob Qual Nurs Res. 2017;4(4):2333393617742282. doi: 10.1177/2333393617742282.
   Google Scholar
• Colorafi KJ, Evans B. Qualitative descriptive methods in health science research. HERD. 2016;9(4):16–25. doi: 10.1177/1937586715614171.
   PubMedGoogle Scholar
• Sandelowski M. What’s in a name? Qualitative description revisited. Res Nurs Health. 2010;33(1):77–84. doi: 10.1002/nur.20362.
   PubMed Web of Science ®Google Scholar
• O’Brien BC, Harris IB, Beckman TJ, et al. Standards for reporting qualitative research: a synthesis of recommendations. Acad Med. 2014;89(9):1245–1251. doi: 10.1097/ACM.0000000000000388.
   PubMed Web of Science ®Google Scholar
• Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349–357. doi: 10.1093/intqhc/mzm042.
   PubMed Web of Science ®Google Scholar
• Sandelowski M, Barroso J. Classifying the findings in qualitative studies. Qual Health Res. 2003;13(7):905–923. doi: 10.1177/1049732303253488.
   PubMed Web of Science ®Google Scholar
• Sandelowski M. Whatever happened to qualitative description? Res Nurs Health. 2000;23(4):334–340. doi: 10.1002/1098-240x(200008)23:4<334::aid-nur9>3.0.co;2-g.
   PubMed Web of Science ®Google Scholar
• Moser A, Korstjens I. Series: Practical guidance to qualitative research. Part 3: sampling, data collection and analysis. Eur J Gen Pract. 2018;24(1):9–18. doi: 10.1080/13814788.2017.1375091.
   PubMed Web of Science ®Google Scholar
• Blumenfeld AM, Silberstein SD, Dodick DW, et al. Insights into the functional anatomy behind the preempt injection paradigm: guidance on achieving optimal outcomes. Headache. 2017;57(5):766–777. doi: 10.1111/head.13074.
   PubMed Web of Science ®Google Scholar
• Turner-Bowker DM, Lamoureux RE, Stokes J, et al. Informing a priori sample size estimation in qualitative concept elicitation interview studies for clinical outcome assessment instrument development. Value Health. 2018;21(7):839–842. doi: 10.1016/j.jval.2017.11.014.
   PubMed Web of Science ®Google Scholar
• Paulus TM, Lester JN. Doing qualitative research in a digital world. Sage, Thousand, Oaks; 2022.
   Google Scholar
• Miles MB, Huberman AM, Saldaña J. Qualitative data analysis. A methods sourcebook. 3rd ed. Thousand Oaks (CA): Sage; 2014.
   Google Scholar
• Nowell LS, Norris JM, White DE, et al. Thematic analysis: striving to meet the trustworthiness criteria. Int J Qual Methods. 2017;16(1):160940691773384. doi: 10.1177/1609406917733847.
   Web of Science ®Google Scholar
• Korstjens I, Moser A. Series: practical guidance to qualitative research. Part 4: trustworthiness and publishing. Eur J Gen Pract. 2018;24(1):120–124. doi: 10.1080/13814788.2017.1375092.
   PubMed Web of Science ®Google Scholar
• Palacios-Ceña D, Neira-Martín B, Silva-Hernández L, et al. Living with chronic migraine: a qualitative study on female patients’ perspectives from a specialised headache clinic in Spain. BMJ Open. 2017;7(8):e017851. doi: 10.1136/bmjopen-2017-017851.
   PubMed Web of Science ®Google Scholar
• Minen MT, Anglin C, Boubour A, et al. Meta-Synthesis on migraine management. Headache. 2018;58(1):22–44. doi: 10.1111/head.13212.
   PubMed Web of Science ®Google Scholar
• Peters M, Abu-Saad HH, Vydelingum V, et al. Patients’ decision-making for migraine and chronic daily headache management. A qualitative study. Cephalalgia. 2003;23(8):833–841. doi: 10.1046/j.1468-2982.2003.00590.x.
   PubMed Web of Science ®Google Scholar
• Peters M, Huijer Abu-Saad H, Vydelingum V, et al. The patients’ perceptions of migraine and chronic daily headache: a qualitative study. J Headache Pain. 2005;6(1):40–47. doi: 10.1007/s10194-005-0144-7.
   PubMedGoogle Scholar
• Ahmed F, Gaul C, García-Moncó JC, et al. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study. J Headache Pain. 2019;20(1):26. doi: 10.1186/s10194-019-0976-1.
   PubMedGoogle Scholar
• Driessen MT, Cohen JM, Thompson SF, et al. Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine. J Headache Pain. 2022;23(1):56. doi: 10.1186/s10194-022-01415-x.
   PubMed Web of Science ®Google Scholar
• Bendtsen L, Sacco S, Ashina M, et al. Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the european headache federation. J Headache Pain. 2018;19(1):91. doi: 10.1186/s10194-018-0921-8.
   PubMedGoogle Scholar
• Domínguez C, Pozo-Rosich P, Torres-Ferrús M, et al. OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study. Eur J Neurol. 2018;25(2):411–416. doi: 10.1111/ene.13523.
   PubMed Web of Science ®Google Scholar
• Gago-Veiga AB, Santos-Lasaosa S, Cuadrado ML, et al. Evidence and experience with onabotulinumtoxinA in chronic migraine: recommendations for daily clinical practice. Neurologia. 2019;34(6):408–417. doi: 10.1016/j.nrl.2017.09.008.
   PubMed Web of Science ®Google Scholar
• Cuadrado Perez ML, López Bravo A, Casas Limón J, et al. I. Bloqueos anestésicos. Infiltración con onabotulinumtoxina. In: Santos Lasaosa S, Pozos Rosich P (eds) Manual de práctica clínica en cefaleas. Sociedad española de neurologia., Madrid: Luzan 5; 2020. https://www.sen.es/pdf/2020/ManualCefaleas2020.pdf
   Google Scholar
• Silberstein SD, Dodick DW, Aurora SK, et al. Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT. J Neurol Neurosurg Psychiatry. 2015;86(9):996–1001. doi: 10.1136/jnnp-2013-307149.
   PubMed Web of Science ®Google Scholar
• Ornello R, Baraldi C, Ahmed F, et al. Excellent response to OnabotulinumtoxinA: different definitions, different predictors. Int J Environ Res Public Health. 2022;19(17):10975. doi: 10.3390/ijerph191710975.
   PubMed Web of Science ®Google Scholar
• Alpuente A, Gallardo VJ, Torres-Ferrús M, et al. Short and mid-term predictors of response to OnabotulinumtoxinA: real-life experience observational study. Headache. 2020;60(4):677–685. doi: 10.1111/head.13765.
   PubMed Web of Science ®Google Scholar
• Dekker F, Knuistingh Neven A, Andriesse B, et al. Prophylactic treatment of migraine; the patient’s view, a qualitative study. BMC Fam Pract. 2012;13(1):13. doi: 10.1186/1471-2296-13-13.
   PubMedGoogle Scholar
• Leonardi M, Raggi A. A narrative review on the burden of migraine: when the burden is the impact on people’s life. J Headache Pain. 2019;20(1):41. doi: 10.1186/s10194-019-0993-0.
   PubMed Web of Science ®Google Scholar
• Torres-Ferrus M, Gallardo VJ, Alpuente A, et al. Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA. J Headache Pain. 2020;21(1):88. doi: 10.1186/s10194-020-01157-8.
   PubMed Web of Science ®Google Scholar
• Hepp Z, Rosen NL, Gillard PG, et al. Comparative effectiveness of onabotulinumtoxinA versus oral migraine prophylactic medications on headache-related resource utilization in the management of chronic migraine: retrospective analysis of a US-based insurance claims database. Cephalalgia. 2016;36(9):862–874. doi: 10.1177/0333102415621294.
   PubMed Web of Science ®Google Scholar
• Kollewe K, Gaul C, Gendolla A, et al. Real-life use of onabotulinumtoxinA reduces healthcare resource utilization in individuals with chronic migraine: the REPOSE study. J Headache Pain. 2021;22(1):50. doi: 10.1186/s10194-021-01260-4.
   PubMed Web of Science ®Google Scholar
• Rothrock JF, Bloudek LM, Houle TT, et al. Real-world economic impact of onabotulinumtoxinA in patients with chronic migraine. Headache. 2014;54(10):1565–1573. doi: 10.1111/head.12456.
   PubMed Web of Science ®Google Scholar
• Ruggeri M. The cost effectiveness of Botox in italian patients with chronic migraine. Neurol Sci. 2014;35(Suppl 1):45–47. doi: 10.1007/s10072-014-1741-5.
   PubMedGoogle Scholar
• Smith M, Nakamoto M, Crocker J, et al. Early impact of the COVID-19 pandemic on outpatient migraine care in Hawaii: results of a quality improvement survey. Headache. 2021;61(1):149–156. doi: 10.1111/head.14030.
   PubMed Web of Science ®Google Scholar
• Al-Hashel JY, Ismail II. Impact of coronavirus disease 2019 (COVID-19) pandemic on patients with migraine: a web-based survey study. J Headache Pain. 2020;21(1):115. doi: 10.1186/s10194-020-01183-6.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Martinez A, Planchuelo-Gómez Á, Guerrero ÁL, et al. Effects of the onabotulinumtoxinA follow-up delay in migraine course during the COVID-19 lockdown. Neurol Sci. 2021;42(12):5087–5092. doi: 10.1007/s10072-021-05180-8.
   PubMed Web of Science ®Google Scholar
• Sebele-Mpofu FY. Saturation controversy in qualitative research: complexities and underlying assumptions. A Literature Review. Cogent Soc Sci. 2020;6(1):1838706.
   Web of Science ®Google Scholar
• Vasileiou K, Barnett J, Thorpe S, et al. Characterising and justifying sample size sufficiency in interview-based studies: systematic analysis of qualitative health research over a 15-year period. BMC Med Res Methodol. 2018;18(1):148. doi: 10.1186/s12874-018-0594-7.
   PubMed Web of Science ®Google Scholar
• Sim J, Saunders B, Waterfield J, et al. Can sample size in qualitative research be determined a priori? Int J Soc Res Method. 2018;21(5):619–634. doi: 10.1080/13645579.2018.1454643.
   Web of Science ®Google Scholar